Benzinga | Nov 2, 2021 10:50AM EDT

ADC Therapeutics Q3 EPS $(0.59) Beats $(0.92) Estimate, Sales $13.15M Beat $7.39M Estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.92) by 35.87 percent. This is a 1.72 percent decrease over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $13.15 million which beat the analyst consensus estimate of $7.39 million by 77.90 percent.